Clinical trial · Observational
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
NCT06229860CI-TRIAL-00105070recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| Chronic Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adult patients with CML in chronic phase (CML-CP)
- interventionNames
- Other: Interview
Primary outcomes (4)
- measure
- Assessment of adherence to TKI medication
- timeFrame
- Up to 1 year
- description
- This will be measured by Morisky Medication Adherence Scale (MMAS), an 8-item tool related to adherence behavior include forgetfulness, stopping medication because of worsening of symptoms or improvement in health condition, and inconvenience of continuing medication. Each item is scored 0 or 1 depending on whether the patient answers yes or no, with a minimum score of 0 and maximum score of 8
- measure
- Personality assessment
- timeFrame
- Up to 1 year
- description
- Patient personality will be assessed using the Mini International Personality Item Pool (mini-IPIP) questionnaire. In the mini-IPIP, each of the five factors (openness, conscientiousness, extraversion, agreeableness and neuroticism) is assessed with four items, making a total of 20 items. Each item is scored on a scale of 1 through 5, with 1 indicating "very inaccurate" and 5 corresponding to "very accurate"
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP) * Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib * A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or * A member of a patient support group organized by the CML Buster Foundation * Do not meet any of the criteria listed under "Exclusion Requirements" Exclusion Criteria: * Unable to read and speak English * Impaired decisional capacity to consent
References
Publications (0)
Data not yet available
No reference posted for this study.